Zalutumumab
Based on 1 Customer Validation
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.34%
- No. CAS: 667901-13-5
- Peso molecular:146.52 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas EGFR
More
Actividad biológica
Descripciòn
Isotype
Human IgG1(K214R) kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
ERBB1/EGFR/HER1
In Vitro
Zalutumumab (0-1 μM; 60 min) effectively blocks EGF-induced EGFR activation with an IC50 value of 1.3 nM[2]. Zalutumumab (0-1 μM; 96 h) affects proliferation of A431 cells[2]. Zalutumumab (10 μg/mL; 24 h) induces a comparable percentage of specificlysis of A431 cells with mouse macrophages[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A431 cell line
-
Concentration:0-1 μM
-
Incubation Time:96 hours
-
Result:Inhibited A431 cells proliferation with an IC50 value of 1.5 nM.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SCID mice with A431 cells injection[3]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction
-
Result:Effectively inhibited tumor growth in A431 xenograft models with an early treatment.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Aplicación
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human EGFR Protein (ECD, His Tag) can bind Zalutumumab. The EC50 for this effect is 5.92 ng/mL. -
Flow Cytometry analysis of A431 cells labelling ERBB1/EGFR/HER1 (red) with Zalutumumab (anti-ERBB1/EGFR/HER1) (HY-P99155). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1(K214R) kappa (HY-P99995). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
No. CAS 667901-13-5
-
Appearance Liquid
-
Peso molecular 146.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Zalutumumab]
-
Synonyms
2F8; HUMAX-EGFR
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Schick U, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012 Jan;12(1):119-25. [Content Brief]
[2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6109-14. [Content Brief]
[3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011 Sep 15;187(6):3383-90. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zalutumumab Related Classifications
HY-P99155 Related Classifications
Powered by Bioz